Alaproclate (INN, USAN) (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.

CAS：60719-82-6
中文别名：
英文别名：Alaproclate [USAN:INN];Alaproclate;2-aminopropanoic acid 1-(4-chlorophenyl)-2-methyl-2-propylester;Alaproclatum [INN-Latin];Alaproclato [INN-Spanish];GEA-654;
分子式：C13H18ClNO2
分子量：255.741
精确质量：255.103
Psa：52.32
Logp：3.2518

UNII：C4R42570ZO

密度：1.14g/cm3
沸点：335.1ºC at 760 mmHg
闪点：156.5ºC
折射率：1.528